Ken Griffin Abb Vie Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $24.6 Million - $30 Million	-150,300 Reduced 5.74%	2,467,500 $487 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $16.9 Million - $19.7 Million	108,900 Added 4.34%	2,617,800 $449 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $450 Million - $513 Million	-2,816,000 Reduced 52.88%	2,508,900 $457 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $207 Million - $233 Million	1,504,200 Added 39.37%	5,324,900 $825 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $173 Million - $201 Million	1,298,100 Added 51.46%	3,820,700 $570 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $62.1 Million - $77.3 Million	-468,500 Reduced 15.66%	2,522,600 $340 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $22.6 Million - $26 Million	156,400 Added 5.52%	2,991,100 $477 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $120 Million - $144 Million	-868,900 Reduced 23.46%	2,834,700 $458 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $32.5 Million - $37.3 Million	242,000 Added 6.99%	3,703,600 $497 Million

3,849

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $321B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.